



# FARADISE Registry: Positive 12-month real-world results

## One of the largest prospective FARAWAVE™ global registries

Favourable procedural and safety outcomes | Positive 12-month clinical effectiveness\*

The FARADISE registry is a global, prospective study evaluating the real-world use of the FARAWAVE Pulsed Field Ablation Catheter with up to 3 years of patient follow-up.

- **48 centres**
- **21 countries** (Europe, Asia, Australia, Middle East)
- **1,158 patients** (65.0% PAF)

Ablation and monitoring protocols were implemented according to each hospital's standard of care.

### SAFETY


**1.5%**

SERIOUS ADVERSE EVENT RATE  
at 12 months



**No reported oesophageal  
fistulas or PV stenosis**

## 12-MONTH CLINICAL EFFECTIVENESS

Paroxysmal vs. non-paroxysmal (PVI vs. PVI+)



**Ablation strategy (PVI vs. PVI+) had no impact on  
12-month clinical effectiveness within AF indication**



## LEARNING CURVE

More FARAWAVE experience led to:

- Greater **procedural efficiency**
- Increased PVI+ procedures

The **clinical effectiveness** was consistent across varying levels of device experience.



## PROCEDURAL INFORMATION

**72.5%** of all procedures had a PVI-only ablation strategy

- Procedure time = **51 min** [40, 70]
- LA dwell = **31 min** [24, 41]
- Fluoroscopy = **12 min** [8, 17]  
(Median, IQR [Q1, Q3])

\*Clinical effectiveness was defined as freedom from arrhythmia recurrence, repeat procedure, and cardioversion.

1. Boersma, Real-World experience with the Pentaspline Pulsed Field Ablation System: One-year outcomes of the FARADISE Registry. ESC, 2025.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at [www.IFU-BSCI.com](http://www.IFU-BSCI.com). Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

© 2025 Boston Scientific Corporation or its affiliates. All rights reserved. EP-2301703-AA C€ 0459